Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.40 |
| ▸ | CDK1 | P06493 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 6/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.40 |
| ▸ | KDR | P35968 | 6/20 | 0.40 |
| ▸ | DCLK1 | O15075 | 5/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.40 |
| ▸ | LCK | P06239 | 5/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.40 |
| ▸ | GSK3A | P49840 | 5/20 | 0.40 |
| ▸ | GSK3B | P49841 | 5/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 5/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28548935 | 0.92 | AURKA (0.41) | AURKAAURKBCDK1CDK2CDK5 | |
| SCHEMBL4423148 | 0.89 | RIPK2 (0.49) | AURKAAURKBCDK1CDK2CDK5 | |
| SCHEMBL4417439 | 0.88 | AURKA (0.39) | AURKAAURKBCDK1CDK2CDK5 | |
| SCHEMBL4413220 | 0.86 | CDK1 (0.40) | AURKAAURKBCDK1CDK2CDK5 | |
| SCHEMBL4413304 | 0.82 | IKBKB (0.49) | AURKAAURKBCDK1CDK2KDR | |
| SCHEMBL4420761 | 0.81 | PKMYT1 (0.40) | AURKAAURKBCDK1CDK2CDK5 | |
| SCHEMBL4414385 | 0.81 | CYP2C19 (0.41) | AURKAAURKBCDK1CDK2CDK5 | |
| SCHEMBL4414503 | 0.81 | RIPK2 (0.49) | AURKAAURKBCDK1CDK2CDK5 | |
| SCHEMBL4422230 | 0.80 | PTK2 (0.44) | CDK2KDRMAP4K4LCKFGFR1 | |
| SCHEMBL28562488 | 0.78 | RIPK2 (0.47) | FGFR1SRCEGFRRIPK2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615921-B1 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | EP | claimed |
| US-7163941-B2 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-01-16 | — | — | US | claimed |
| EP-1615921-A2 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | claimed |
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (DE) | 2005-06-16 | — | — | US | claimed |
| WO-2004085436-A2 | PYRIDO[2,3-D]PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| EP-1615921-B1 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-7163941-B2 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1615921-A2 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (DE) | 2005-06-16 | — | — | US | disclosed |
| WO-2004085436-A2 | PYRIDO[2,3-D]PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | AURKA 1018/4885AURKB 664/4885CDK1 1194/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | AURKA 1514/4885AURKB 1003/4885CDK1 1293/4885 |
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | LCK, TYRO3, ABL1 | AURKA 577/4885AURKB 702/4885CDK1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.